AAV Gene Therapy for MPS IVA with Induction of Immune Tolerance via Oral Administration of Epitope Peptides of N-Acetylgalactosamine-6-sulfate Sulfatase
Open Access
- 28 February 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (5) , 2278
Abstract
Mucopolysaccharidosis IVA (MPS IVA) is caused by the accumulation of undegraded glycosaminoglycans due to the deficiency of the N-acetylgalactosamine-6-sulfate sulfatase (GALNS) enzyme. MPS IVA manifests as progressive systemic skeletal dysplasia. Gene therapy (GT) is potentially a one-time treatment in which the enzyme is continuously produced, circulated, and delivered to target tissues. However, immune responses to gene products can diminish therapeutic efficacy. We hypothesized that oral delivery of tolerogenic peptides induces immune tolerance to human GALNS (hGALNS) in MPS IVA mice, enhancing therapeutic efficacy. Neonatal mice deficient in mouse GALNS (mGALNS) were treated orally with three T-cell/B-cell epitope peptides or hGALNS protein on alternate days from day 3 after birth to day 20 before intravenous injection with AAV9 vectors encoding human GALNS on day 30. The results are encouraging, with anti-hGALNS antibodies undetectable in the plasma of orally administered peptide groups. hGALNS enzyme activities in plasma and tissues were higher in the orally treated groups than in the non-tolerized control group. Keratan sulfate levels in plasma, liver, and bone were normalized. Complete correction for heart vacuolization was achieved in peptide-treated groups, and partial correction for bone pathology was observed in all GT-treated groups. Overall, oral tolerance induction using immunodominant peptides promises to significantly enhance the efficacy of AAV-GT for MPS IVA.Keywords
Funding Information
- Austrian MPS society, A Cure for Robert, Inc.
- The Morquio Community and Angelo Cali Family
- Bennett Foundation
- Fighting For Freya Foundation
- Scarlett Griffith Foundation
- Nemours Funds
- National Institutes of Health (1R01HD102545-01A1)
This publication has 58 references indexed in Scilit:
- Oral and Sublingual Immunotherapy for Treatment of IgE-Mediated Food AllergyClinical Reviews in Allergy & Immunology, 2018
- Targeted delivery of antigen to intestinal dendritic cells induces oral tolerance and prevents autoimmune diabetes in NOD miceDiabetologia, 2018
- Newborn screening for mucopolysaccharidoses: a pilot study of measurement of glycosaminoglycans by tandem mass spectrometryJournal of Inherited Metabolic Disease, 2016
- Gene therapy on the moveEMBO Molecular Medicine, 2013
- Assessment of bone dysplasia by micro‐CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VIIJournal of Inherited Metabolic Disease, 2012
- Epitope‐specific immunotherapy of rheumatoid arthritis: Clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double‐blind, placebo‐controlled, pilot phase II trialArthritis & Rheumatism, 2009
- Oral Administration of Insulin to Neonates Suppresses Spontaneous and Cyclophosphamide Induced Diabetes in the NOD MouseJournal of Autoimmunity, 2001
- Treatment of rheumatoid arthritis with oral type II collagen: Results of a multicenter, double-blind, placebo-controlled trialArthritis & Rheumatism, 1998
- Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic proteinCellular Immunology, 1988
- Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragmentsJournal of Neuroimmunology, 1987